Odyssey shakes hands on $500m-plus deal for Linden’s ProPharma Group

Odyssey previously weighed buying ProPharma through existing portfolio company TrialCard, three sources said.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this